25 XP   0   0   10

Imugene Ltd
Buy, Hold or Sell?

Let's analyse Imugene together

PenkeI guess you are interested in Imugene Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Imugene Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Imugene Ltd

I send you an email if I find something interesting about Imugene Ltd.

Quick analysis of Imugene (30 sec.)










What can you expect buying and holding a share of Imugene? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.03
Expected worth in 1 year
A$0.05
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
A$0.03
Return On Investment
22.4%

For what price can you sell your share?

Current Price per Share
A$0.12
Expected price per share
A$0.105 - A$0.127
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Imugene (5 min.)




Live pricePrice per Share (EOD)

A$0.12

Intrinsic Value Per Share

A$-0.06 - A$-0.03

Total Value Per Share

A$-0.03 - A$-0.01

2. Growth of Imugene (5 min.)




Is Imugene growing?

Current yearPrevious yearGrowGrow %
How rich?$122.9m$90.5m$32.4m26.4%

How much money is Imugene making?

Current yearPrevious yearGrowGrow %
Making money-$25.5m-$24.7m-$779.9k-3.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Imugene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#360 / 1045

Most Revenue
#874 / 1045

Most Profit
#798 / 1045

Most Efficient
#264 / 1045
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Imugene? (5 min.)

Welcome investor! Imugene's management wants to use your money to grow the business. In return you get a share of Imugene.

What can you expect buying and holding a share of Imugene?

First you should know what it really means to hold a share of Imugene. And how you can make/lose money.

Speculation

The Price per Share of Imugene is A$0.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Imugene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Imugene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.03. Based on the TTM, the Book Value Change Per Share is A$0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Imugene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-2.8%0.00-2.8%0.00-2.8%0.00-1.7%0.00-0.9%
Usd Book Value Change Per Share0.003.7%0.003.7%0.015.4%0.002.5%0.001.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.003.7%0.003.7%0.015.4%0.002.5%0.001.4%
Usd Price Per Share0.06-0.06-0.12-0.09-0.05-
Price to Earnings Ratio-17.75--17.75--35.14--46.43--42.71-
Price-to-Total Gains Ratio13.55-13.55-18.06-110.47-120.32-
Price to Book Ratio3.57-3.57-9.60-12.34-11.66-
Price-to-Total Gains Ratio13.55-13.55-18.06-110.47-120.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.078312
Number of shares12769
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (12769 shares)55.9738.97
Gains per Year (12769 shares)223.90155.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102242140156146
204484380312302
306726620468458
408968860624614
50111911100779770
60134313340935926
7015671558010911082
8017911782012471238
9020152006014031394
10022392230015591550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%4.026.01.012.9%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%18.013.00.058.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.031.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%18.013.00.058.1%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Imugene

About Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Fundamental data was last updated by Penke on 2024-02-26 23:09:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Imugene Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Imugene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Imugene Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-103.5%+103.5%
5Y-103.5%10Y-932.4%+828.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--188.7%+188.7%
TTM--211.4%+211.4%
YOY--286.5%+286.5%
5Y-103.5%-469.5%+366.0%
10Y-932.4%-609.8%-322.6%
1.1.2. Return on Assets

Shows how efficient Imugene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • -20.0% Return on Assets means that Imugene generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Imugene Ltd:

  • The MRQ is -20.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.0%TTM-20.0%0.0%
TTM-20.0%YOY-25.7%+5.7%
TTM-20.0%5Y-25.8%+5.8%
5Y-25.8%10Y-25.2%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.0%-12.7%-7.3%
TTM-20.0%-12.4%-7.6%
YOY-25.7%-11.4%-14.3%
5Y-25.8%-13.9%-11.9%
10Y-25.2%-15.6%-9.6%
1.1.3. Return on Equity

Shows how efficient Imugene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • -20.8% Return on Equity means Imugene generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Imugene Ltd:

  • The MRQ is -20.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.8%TTM-20.8%0.0%
TTM-20.8%YOY-27.4%+6.6%
TTM-20.8%5Y-28.1%+7.3%
5Y-28.1%10Y-28.6%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.8%-16.3%-4.5%
TTM-20.8%-16.2%-4.6%
YOY-27.4%-14.7%-12.7%
5Y-28.1%-19.1%-9.0%
10Y-28.6%-20.0%-8.6%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Imugene Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Imugene is operating .

  • Measures how much profit Imugene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Imugene Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-84.1%+84.1%
5Y-84.1%10Y-460.5%+376.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--302.9%+302.9%
TTM--220.2%+220.2%
YOY--288.3%+288.3%
5Y-84.1%-461.8%+377.7%
10Y-460.5%-610.0%+149.5%
1.2.2. Operating Ratio

Measures how efficient Imugene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Imugene Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.252-1.252
5Y1.25210Y6.904-5.652
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.963-2.963
TTM-3.251-3.251
YOY-3.828-3.828
5Y1.2525.978-4.726
10Y6.9047.505-0.601
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Imugene Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Imugene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 27.02 means the company has $27.02 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Imugene Ltd:

  • The MRQ is 27.022. The company is very able to pay all its short-term debts. +2
  • The TTM is 27.022. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ27.022TTM27.0220.000
TTM27.022YOY15.323+11.699
TTM27.0225Y14.411+12.611
5Y14.41110Y12.789+1.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.0224.010+23.012
TTM27.0224.478+22.544
YOY15.3235.577+9.746
5Y14.4116.222+8.189
10Y12.7896.568+6.221
1.3.2. Quick Ratio

Measures if Imugene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Quick Ratio of 26.96 means the company can pay off $26.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Imugene Ltd:

  • The MRQ is 26.956. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 26.956. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ26.956TTM26.9560.000
TTM26.956YOY15.174+11.783
TTM26.9565Y14.334+12.622
5Y14.33410Y12.714+1.620
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.9563.566+23.390
TTM26.9564.169+22.787
YOY15.1745.472+9.702
5Y14.3346.097+8.237
10Y12.7146.383+6.331
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Imugene Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Imugene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Imugene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Imugene assets are financed with 3.8% credit (debt) and the remaining percentage (100% - 3.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Imugene Ltd:

  • The MRQ is 0.038. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.038. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.038TTM0.0380.000
TTM0.038YOY0.060-0.022
TTM0.0385Y0.078-0.040
5Y0.07810Y0.112-0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0380.332-0.294
TTM0.0380.329-0.291
YOY0.0600.262-0.202
5Y0.0780.371-0.293
10Y0.1120.380-0.268
1.4.2. Debt to Equity Ratio

Measures if Imugene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 3.9% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Imugene Ltd:

  • The MRQ is 0.039. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.039. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.039TTM0.0390.000
TTM0.039YOY0.064-0.025
TTM0.0395Y0.085-0.046
5Y0.08510Y0.131-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0390.375-0.336
TTM0.0390.396-0.357
YOY0.0640.317-0.253
5Y0.0850.425-0.340
10Y0.1310.477-0.346
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Imugene Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Imugene generates.

  • Above 15 is considered overpriced but always compare Imugene to the Biotechnology industry mean.
  • A PE ratio of -17.75 means the investor is paying $-17.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Imugene Ltd:

  • The EOD is -23.401. Based on the earnings, the company is expensive. -2
  • The MRQ is -17.746. Based on the earnings, the company is expensive. -2
  • The TTM is -17.746. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-23.401MRQ-17.746-5.655
MRQ-17.746TTM-17.7460.000
TTM-17.746YOY-35.144+17.398
TTM-17.7465Y-46.429+28.683
5Y-46.42910Y-42.714-3.714
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-23.401-2.636-20.765
MRQ-17.746-2.324-15.422
TTM-17.746-2.801-14.945
YOY-35.144-4.414-30.730
5Y-46.429-6.185-40.244
10Y-42.714-6.292-36.422
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Imugene Ltd:

  • The EOD is -28.193. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.380. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -21.380. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.193MRQ-21.380-6.813
MRQ-21.380TTM-21.3800.000
TTM-21.380YOY-42.759+21.380
TTM-21.3805Y-47.641+26.262
5Y-47.64110Y-42.573-5.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.193-3.656-24.537
MRQ-21.380-2.911-18.469
TTM-21.380-3.541-17.839
YOY-42.759-6.023-36.736
5Y-47.641-8.362-39.279
10Y-42.573-8.792-33.781
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Imugene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.57 means the investor is paying $3.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Imugene Ltd:

  • The EOD is 4.710. Based on the equity, the company is fair priced.
  • The MRQ is 3.572. Based on the equity, the company is fair priced.
  • The TTM is 3.572. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.710MRQ3.572+1.138
MRQ3.572TTM3.5720.000
TTM3.572YOY9.595-6.023
TTM3.5725Y12.341-8.769
5Y12.34110Y11.661+0.680
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.7102.155+2.555
MRQ3.5721.883+1.689
TTM3.5722.134+1.438
YOY9.5953.019+6.576
5Y12.3413.616+8.725
10Y11.6614.009+7.652
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Imugene Ltd.

3.1. Funds holding Imugene Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-01-31DFA International Sustainability Core 1 Portfolio0.029999999-1293602--
Total 0.0299999990129360200.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Imugene Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0070.0070%0.010-33%0.005+44%0.003+166%
Book Value Per Share--0.0250.0250%0.019+36%0.013+97%0.007+257%
Current Ratio--27.02227.0220%15.323+76%14.411+88%12.789+111%
Debt To Asset Ratio--0.0380.0380%0.060-37%0.078-51%0.112-66%
Debt To Equity Ratio--0.0390.0390%0.064-38%0.085-54%0.131-70%
Dividend Per Share----0%-0%-0%-0%
Eps---0.005-0.0050%-0.0050%-0.003-41%-0.002-67%
Free Cash Flow Per Share---0.004-0.0040%-0.004-1%-0.003-36%-0.002-63%
Free Cash Flow To Equity Per Share--0.0070.0070%0.009-27%0.004+81%0.002+244%
Gross Profit Margin--1.0131.0130%1.009+0%1.020-1%1.012+0%
Intrinsic Value_10Y_max---0.032--------
Intrinsic Value_10Y_min---0.060--------
Intrinsic Value_1Y_max---0.002--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.007--------
Intrinsic Value_3Y_min---0.014--------
Intrinsic Value_5Y_max---0.013--------
Intrinsic Value_5Y_min---0.026--------
Market Cap887258419.200+24%672837634.560672837634.5600%1330887628.800-49%995208193.536-32%552761995.162+22%
Net Profit Margin----0%-0%-1.0350%-9.3240%
Operating Margin----0%-0%-0.8410%-4.6050%
Operating Ratio----0%-0%1.252-100%6.904-100%
Pb Ratio4.710+24%3.5723.5720%9.595-63%12.341-71%11.661-69%
Pe Ratio-23.401-32%-17.746-17.7460%-35.144+98%-46.429+162%-42.714+141%
Price Per Share0.120+24%0.0910.0910%0.180-49%0.135-32%0.075+22%
Price To Free Cash Flow Ratio-28.193-32%-21.380-21.3800%-42.759+100%-47.641+123%-42.573+99%
Price To Total Gains Ratio17.865+24%13.54813.5480%18.061-25%110.466-88%120.324-89%
Quick Ratio--26.95626.9560%15.174+78%14.334+88%12.714+112%
Return On Assets---0.200-0.2000%-0.257+29%-0.258+29%-0.252+26%
Return On Equity---0.208-0.2080%-0.274+32%-0.281+35%-0.286+37%
Total Gains Per Share--0.0070.0070%0.010-33%0.005+44%0.003+166%
Usd Book Value--122930139.964122930139.9640%90518715.934+36%62544321.132+97%34482357.852+257%
Usd Book Value Change Per Share--0.0040.0040%0.007-33%0.003+44%0.002+166%
Usd Book Value Per Share--0.0170.0170%0.012+36%0.008+97%0.005+257%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.003-0.0030%-0.0030%-0.002-41%-0.001-67%
Usd Free Cash Flow---20537945.886-20537945.8860%-20312261.796-1%-13221908.717-36%-7587836.193-63%
Usd Free Cash Flow Per Share---0.003-0.0030%-0.003-1%-0.002-36%-0.001-63%
Usd Free Cash Flow To Equity Per Share--0.0050.0050%0.006-27%0.003+81%0.001+244%
Usd Market Cap579024844.370+24%439093840.314439093840.3140%868537266.555-49%649472867.102-32%360732478.042+22%
Usd Price Per Share0.078+24%0.0590.0590%0.117-49%0.088-32%0.049+22%
Usd Profit---25563046.155-25563046.1550%-24783084.087-3%-16351076.511-36%-9071401.888-65%
Usd Revenue----0%-0%1142294.072-100%921236.917-100%
Usd Total Gains Per Share--0.0040.0040%0.007-33%0.003+44%0.002+166%
 EOD+6 -2MRQTTM+0 -0YOY+12 -185Y+18 -1410Y+21 -11

4.2. Fundamental Score

Let's check the fundamental score of Imugene Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-23.401
Price to Book Ratio (EOD)Between0-14.710
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than126.956
Current Ratio (MRQ)Greater than127.022
Debt to Asset Ratio (MRQ)Less than10.038
Debt to Equity Ratio (MRQ)Less than10.039
Return on Equity (MRQ)Greater than0.15-0.208
Return on Assets (MRQ)Greater than0.05-0.200
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Imugene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.811
Ma 20Greater thanMa 500.112
Ma 50Greater thanMa 1000.110
Ma 100Greater thanMa 2000.092
OpenGreater thanClose0.125
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Income Tax Expense  04,0794,0793,2327,311-7,205107-1,957-1,850
Total Other Income Expense Net -61-5-106-111-101-21210,48110,270



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets195,807
Total Liabilities7,437
Total Stockholder Equity188,370
 As reported
Total Liabilities 7,437
Total Stockholder Equity+ 188,370
Total Assets = 195,807

Assets

Total Assets195,807
Total Current Assets164,401
Long-term Assets31,405
Total Current Assets
Cash And Cash Equivalents 153,151
Net Receivables 10,849
Other Current Assets 402
Total Current Assets  (as reported)164,401
Total Current Assets  (calculated)164,401
+/-0
Long-term Assets
Property Plant Equipment 683
Long Term Investments 218
Intangible Assets 30,486
Long-term Assets Other 19
Long-term Assets  (as reported)31,405
Long-term Assets  (calculated)31,405
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,084
Long-term Liabilities1,353
Total Stockholder Equity188,370
Total Current Liabilities
Short-term Debt 191
Accounts payable 2,341
Other Current Liabilities 1,923
Total Current Liabilities  (as reported)6,084
Total Current Liabilities  (calculated)4,455
+/- 1,629
Long-term Liabilities
Long term Debt Total 362
Other Liabilities 991
Long-term Liabilities  (as reported)1,353
Long-term Liabilities  (calculated)1,353
+/- 0
Total Stockholder Equity
Common Stock314,402
Retained Earnings -142,692
Accumulated Other Comprehensive Income 16,660
Total Stockholder Equity (as reported)188,370
Total Stockholder Equity (calculated)188,370
+/-0
Other
Capital Stock314,402
Cash And Equivalents49,543
Cash and Short Term Investments 153,151
Common Stock Shares Outstanding 5,637,197
Current Deferred Revenue1,629
Liabilities and Stockholders Equity 195,807
Net Debt -152,597
Net Invested Capital 188,370
Net Tangible Assets 159,140
Net Working Capital 158,317
Property Plant and Equipment Gross 1,022
Short Long Term Debt Total 553



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-30
> Total Assets 
5,698
11,313
11,926
9,249
8,693
7,891
6,893
3,682
2,441
844
8,144
6,016
9,064
7,268
5,260
5,163
5,763
4,099
4,687
1,318
2,584
8,631
9,115
9,536
12,678
16,914
30,779
65,205
71,809
147,606
195,807
195,807147,60671,80965,20530,77916,91412,6789,5369,1158,6312,5841,3184,6874,0995,7635,1635,2607,2689,0646,0168,1448442,4413,6826,8937,8918,6939,24911,92611,3135,698
   > Total Current Assets 
166
5,984
2,019
1,516
3,145
2,962
2,483
795
264
827
2,663
1,350
4,743
3,281
1,626
1,870
2,818
1,494
2,425
1,318
619
1,758
2,515
2,913
6,054
9,833
23,424
34,495
36,319
113,766
164,401
164,401113,76636,31934,49523,4249,8336,0542,9132,5151,7586191,3182,4251,4942,8181,8701,6263,2814,7431,3502,6638272647952,4832,9623,1451,5162,0195,984166
       Cash And Cash Equivalents 
18
5,558
251
0
2,035
1,814
2,108
402
29
783
2,618
963
4,346
2,697
1,099
1,620
2,487
793
1,906
1,017
566
1,223
1,957
1,583
4,814
7,822
19,048
30,107
29,487
99,888
153,151
153,15199,88829,48730,10719,0487,8224,8141,5831,9571,2235661,0171,9067932,4871,6201,0992,6974,3469632,618783294022,1081,8142,03502515,55818
       Short-term Investments 
0
0
460
387
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000038746000
       Net Receivables 
148
73
193
45
126
666
144
27
61
44
39
385
391
41
1
61
41
181
53
267
54
524
541
1,313
1,220
1,915
4,215
4,194
6,662
12,768
10,849
10,84912,7686,6624,1944,2151,9151,2201,31354152454267531814161141391385394461271446661264519373148
       Other Current Assets 
0
0
0
0
0
0
0
102
0
0
45
387
397
542
525
190
290
520
466
301
0
11
17
18
20
96
160
194
170
1,110
402
4021,1101701941609620181711030146652029019052554239738745001020000000
   > Long-term Assets 
5,532
5,329
9,907
7,733
5,548
4,929
4,410
2,887
2,176
18
5,481
4,666
4,321
3,988
3,634
3,293
2,945
2,605
2,262
1
1,965
6,874
6,600
6,623
6,623
7,081
7,356
30,710
35,490
33,840
31,405
31,40533,84035,49030,7107,3567,0816,6236,6236,6006,8741,96512,2622,6052,9453,2933,6343,9884,3214,6665,481182,1762,8874,4104,9295,5487,7339,9075,3295,532
       Property Plant Equipment 
28
449
2,522
2,326
2,228
1,916
1,805
1,040
607
18
19
19
15
22
10
10
3
4
2
1
0
0
0
3
3
4
233
156
466
863
683
6838634661562334330001243101022151919186071,0401,8051,9162,2282,3262,52244928
       Goodwill 
0
0
0
0
0
1
1
1
1
0
4,987
4,648
4,307
0
0
0
0
0
0
0
961
0
0
0
0
0
0
0
0
0
0
000000000096100000004,3074,6484,9870111100000
       Long Term Investments 
0
0
0
0
0
0
450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
50
81
115
252
218
2182521158150202000000000000000000450000000
       Intangible Assets 
4,000
3,692
3,385
3,077
2,770
2,462
2,154
1,847
1,568
0
4,987
4,648
4,307
3,965
3,624
3,283
2,942
2,601
2,260
0
1,005
6,874
6,600
6,600
6,600
7,057
7,057
30,458
34,893
32,689
30,486
30,48632,68934,89330,4587,0577,0576,6006,6006,6006,8741,00502,2602,6012,9423,2833,6243,9654,3074,6484,98701,5681,8472,1542,4622,7703,0773,3853,6924,000
       Long-term Assets Other 
911
566
4,000
2,330
550
550
450
0
0
1
475
0
0
0
0
0
0
0
0
0
0
0
0
20
0
7,081
16
16
16
35
19
19351616167,0810200000000000004751004505505502,3304,000566911
> Total Liabilities 
587
127
1,305
1,127
1,241
1,136
898
903
2,667
52
701
584
412
806
561
493
437
307
480
245
698
1,899
1,383
1,679
1,283
1,439
3,485
5,399
6,791
8,901
7,437
7,4378,9016,7915,3993,4851,4391,2831,6791,3831,899698245480307437493561806412584701522,6679038981,1361,2411,1271,305127587
   > Total Current Liabilities 
264
127
840
601
1,009
969
755
709
2,667
52
701
584
412
806
561
493
437
307
480
245
167
697
397
694
297
438
2,424
2,899
4,457
7,425
6,084
6,0847,4254,4572,8992,424438297694397697167245480307437493561806412584701522,6677097559691,009601840127264
       Short-term Debt 
0
0
460
387
0
0
241
286
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59
61
106
184
191
1911841066159000000000000000001,2152862410038746000
       Short Long Term Debt 
0
0
0
0
0
0
241
286
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,215286241000000
       Accounts payable 
0
0
0
0
0
0
338
431
798
47
422
552
285
689
419
380
269
169
74
117
97
155
98
265
16
289
1,479
1,013
760
4,513
2,341
2,3414,5137601,0131,4792891626598155971177416926938041968928555242247798431338000000
       Other Current Liabilities 
220
78
-233
10
656
669
417
501
1,869
5
279
33
127
117
142
114
168
138
407
128
70
542
300
428
281
150
886
1,435
2,853
1,423
1,923
1,9231,4232,8531,435886150281428300542701284071381681141421171273327951,86950141766965610-23378220
   > Long-term Liabilities 
323
0
465
526
232
167
143
194
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
1,061
2,499
2,334
1,476
1,353
1,3531,4762,3342,4991,0611,0019859859851,2025310000000000001941431672325264650323
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
985
985
1,050
8
165
489
362
36248916581,050985985000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
50
52
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
997
2,491
2,169
987
991
9919872,1692,4919971,0019859859851,2025310000000000005250000000
> Total Stockholder Equity
5,111
11,186
10,621
8,122
7,452
6,755
5,995
2,779
-227
793
7,443
5,432
8,653
6,462
4,700
4,670
5,326
3,791
4,207
1,073
1,886
6,732
7,732
7,857
11,395
15,475
27,295
59,806
65,018
138,705
188,370
188,370138,70565,01859,80627,29515,47511,3957,8577,7326,7321,8861,0734,2073,7915,3264,6704,7006,4628,6535,4327,443793-2272,7795,9956,7557,4528,12210,62111,1865,111
   Common Stock
4,665
9,115
9,585
10,628
12,162
14,364
24,352
25,556
26,714
28,516
36,751
8,165
13,180
13,180
13,180
14,907
14,907
14,907
14,907
14,907
17,280
24,242
27,682
30,407
36,335
44,286
63,122
92,798
113,107
230,789
314,402
314,402230,789113,10792,79863,12244,28636,33530,40727,68224,24217,28014,90714,90714,90714,90714,90713,18013,18013,1808,16536,75128,51626,71425,55624,35214,36412,16210,6289,5859,1154,665
   Retained Earnings -142,692-103,521-65,652-47,310-36,817-29,110-26,143-23,647-20,916-18,476-16,360-14,800-11,667-12,082-10,547-11,197-9,286-6,982-4,527-2,733-29,308-27,963-29,802-25,760-21,341-16,411-11,865-9,683-5,439-3,304-2,429
   Accumulated Other Comprehensive Income 
-28
-48
-120
-211
-330
-479
-588
-822
-796
-36
-4
-11
-18
265
806
960
966
966
966
966
966
966
966
1,096
1,202
300
989
14,319
17,563
11,437
16,660
16,66011,43717,56314,3199893001,2021,096966966966966966966966960806265-18-11-4-36-796-822-588-479-330-211-120-48-28
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
2,903
5,423
6,595
7,388
7,485
9,281
3,572
3,806
3,658
276
0
0
0
0
0
0
0
0
0
0
0
971
997
1,096
1,202
300
989
-45,487
-47,455
-127,268
-172,966
-172,966-127,268-47,455-45,4879893001,2021,096997971000000000002763,6583,8063,5729,2817,4857,3886,5955,4232,903



Balance Sheet

Currency in AUD. All numbers in thousands.